Pyxis Oncology, Inc. Income Statement
PYXS|2 years of annual SEC 10-K data (FY2024-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Pyxis Oncology, Inc. reported $16M in revenue and $77M in net loss for FY2025. Revenue increased 0.0% from FY2024 to FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $16.1M | $16.1M |
| Cost of Revenue | $475.0K | $475.0K |
| SG&A Expense | $25.4M | $32.6M |
| R&D Expense | $58.7M | $49.6M |
| Operating Income | -$89.5M | -$82.2M |
| Income Tax | -$2.2M | -$2.2M |
| Net Income | -$77.3M | -$73.8M |
| EPS (Basic) | -$1.32 | -$1.85 |
| EPS (Diluted) | -$1.32 | -$1.85 |
| Shares Outstanding | 60.0M | 44.8M |
| Operating Margin | -554.1% | -509.1% |
| Profit Margin | -479.0% | -457.0% |